Dulaglutide
Once-weekly GLP-1 receptor agonist fused to IgG4 Fc fragment. Eli Lilly's earlier weekly GLP-1 prior to tirzepatide.
FDA-approved as Trulicity. AWARD trials demonstrated A1C reduction and modest weight loss in T2D. Cardiovascular outcomes positive (REWIND). Now generally outperformed by semaglutide / tirzepatide on weight endpoints.
Less weight-loss potency than semaglutide/tirzepatide. Same class-wide watches. Often the formulary-cheaper covered option.
Known risk or pharmacological conflict.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
- BModerate evidence
Dulaglutide — primary mechanism: once-weekly glp-1 receptor agonist fused to igg4 fc fragment. eli lilly's earlier weekly glp-1 prior to tirzepatide.
1 supporting referencesVerified 5d ago
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Pre-filled with this compound's published dose range: 0.75-4.5 mg · weekly, subcutaneous
Draw volume exceeds 100 units (1 mL). Either reduce dose or split into multiple injections.
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
FDA approved (Trulicity)